The Use of Bruton Tyrosine Kinase Inhibitors in Waldenstrom's Macroglobulinemia

被引：1

作者：

Khan, Abdullah Mohammad ^{[1
]}

机构：

[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2022年 / 12卷 / 05期

关键词：

Waldenstrom's macroglobulinemia; Bruton tyrosine kinase inhibitor; ibrutinib; acalabrutinib; zanubrutinib; CONSENSUS PANEL RECOMMENDATIONS; BENDAMUSTINE PLUS RITUXIMAB; 2ND INTERNATIONAL WORKSHOP; IBRUTINIB RESISTANCE; 1ST-LINE TREATMENT; GENOMIC LANDSCAPE; SOMATIC MUTATION; OPEN-LABEL; IN-VIVO; MYD88;

D O I：

10.3390/jpm12050676

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Waldenstrom's macroglobulinemia (WM) remains an incurable malignancy. However, a number of treatment options exist for patients with WM, including alkylating agents, anti-CD20 monoclonal antibodies, and small molecule inhibitors such as proteasome inhibitors and Bruton tyrosine kinase inhibitors (BTKi). The focus of this review is to highlight the role of BTKi in the management of WM. The first BTKi to receive US Food and Drug Administration approval for WM was ibrutinib. Ibrutinib has been extensively studied in both treatment-naive WM patients and in those with relapsed/refractory disease. The next BTKi approved for use was zanubrutinib, and prospective data for acalabrutinib and tirabrutinib have also recently been published. Efficacy data for BTKi will be discussed, as well as the differences in their adverse event profiles.

引用

页数：11

共 47 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2] A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia [J].

An, Gang ;

Zhou, Daobin ;

Cheng, Shu ;

Zhou, Keshu ;

Li, Jianyong ;

Zhou, Jianfeng ;

Xie, Liping ;

Jin, Jie ;

Zhong, Liye ;

Yan, Lingzhi ;

Guo, Haiyi ;

Du, Chenmu ;

Zhong, Jinhua ;

Yu, Yiling ;

Wu, Binghao ;

Qiu, Lugui .

CLINICAL CANCER RESEARCH, 2021, 27 (20) :5492-5501

[3] Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile [J].

Barf, Tjeerd ;

Covey, Todd ;

Izumi, Raquel ;

van de Kar, Bas ;

Gulrajani, Michael ;

van Lith, Bart ;

van Hoek, Maaike ;

de Zwart, Edwin ;

Mittag, Diana ;

Demont, Dennis ;

Verkaik, Saskia ;

Krantz, Fanny ;

Pearson, Paul G. ;

Ulrich, Roger ;

Kaptein, Allard .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02) :240-252

[4] Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study [J].

Buske, Christian ;

Tedeschi, Alessandra ;

Trotman, Judith ;

Garcia-Sanz, Ramon ;

MacDonald, David ;

Leblond, Veronique ;

Mahe, Beatrice ;

Herbaux, Charles ;

Matous, Jeffrey V. ;

Tam, Constantine S. ;

Heffner, Leonard T. ;

Varettoni, Marzia ;

Palomba, M. Lia ;

Shustik, Chaim ;

Kastritis, Efstathios ;

Treon, Steven P. ;

Ping, Jerry ;

Hauns, Bernhard ;

Arango-Hisijara, Israel ;

Dimopoulos, Meletios A. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (01) :52-+

[5] The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia [J].

Cao, Y. ;

Hunter, Z. R. ;

Liu, X. ;

Xu, L. ;

Yang, G. ;

Chen, J. ;

Patterson, C. J. ;

Tsakmaklis, N. ;

Kanan, S. ;

Rodig, S. ;

Castillo, J. J. ;

Treon, S. P. .

LEUKEMIA, 2015, 29 (01) :169-176

[6] Venetoclax in Previously Treated Waldenstrom Macroglobulinemia [J].

Castillo, Jorge J. ;

Allan, John N. ;

Siddiqi, Tanya ;

Advani, Ranjana H. ;

Meid, Kirsten ;

Leventoff, Carly ;

White, Timothy P. ;

Flynn, Catherine A. ;

Sarosiek, Shayna ;

Branagan, Andrew R. ;

Demos, Maria G. ;

Guerrera, Maria L. ;

Kofides, Amanda ;

Liu, Xia ;

Munshi, Manit ;

Tsakmaklis, Nicholas ;

Xu, Lian ;

Yang, Guang ;

Patterson, Christopher J. ;

Hunter, Zachary R. ;

Davids, Matthew S. ;

Furman, Richard R. ;

Treon, Steven P. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (01) :63-+

[7] Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib [J].

Castillo, Jorge J. ;

Abeykoon, Jithma P. ;

Gustine, Joshua N. ;

Zanwar, Saurabh ;

Mein, Kirsten ;

Flynn, Catherine A. ;

Demos, Maria G. ;

Guerrera, Maria L. ;

Kofides, Amanda ;

Liu, Xia ;

Munshi, Manit ;

Tsakmaklis, Nickolas ;

King, Rebecca ;

Yang, Guang ;

Hunter, Zachary R. ;

Advani, Ranjana H. ;

Palomba, Maria Lia ;

Ansell, Stephen M. ;

Gertz, Morie A. ;

Kapoor, Prashant ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (03) :542-550

[8] Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenstrom macroglobulinaemia [J].

Castillo, Jorge J. ;

Gustine, Joshua N. ;

Meid, Kirsten ;

Dubeau, Toni ;

Severns, Patricia ;

Xu, Lian ;

Yang, Guang ;

Hunter, Zachary R. ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (06) :1011-1014

[9] BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism [J].

Chen, Jiaji G. ;

Liu, Xia ;

Munshi, Manit ;

Xu, Lian ;

Tsakmaklis, Nicholas ;

Demos, Maria G. ;

Kofides, Amanda ;

Guerrera, Maria Luisa ;

Chan, Gloria G. ;

Patterson, Christopher J. ;

Meid, Kirsten ;

Gustine, Joshua ;

Dubeau, Toni ;

Severns, Patricia ;

Castillo, Jorge J. ;

Hunter, Zachary R. ;

Wang, Jinhua ;

Buhrlage, Sara J. ;

Gray, Nathanael S. ;

Treon, Steven P. ;

Yang, Guang .

BLOOD, 2018, 131 (18) :2047-2059

[10] Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia [J].

Dimopoulos, M. A. ;

Tedeschi, A. ;

Trotman, J. ;

Garcia-Sanz, R. ;

Macdonald, D. ;

Leblond, V. ;

Mahe, B. ;

Herbaux, C. ;

Tam, C. ;

Orsucci, L. ;

Palomba, M. L. ;

Matous, J. V. ;

Shustik, C. ;

Kastritis, E. ;

Treon, S. P. ;

Li, J. ;

Salman, Z. ;

Graef, T. ;

Buske, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2399-2410

← 1 2 3 4 5 →